Innovations for next-generation antibody-drug conjugates
Dr Amrik Basran and Dr Matt Vincent discuss various developments for antibody-drug conjugates to treat cancer.
List view / Grid view
Dr Amrik Basran and Dr Matt Vincent discuss various developments for antibody-drug conjugates to treat cancer.
17 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The extension agreement will trigger a €1 million payment to Ablynx, and MSD will extend their funding of the research collaboration to September 2018...
25 November 2015 | By
Ablynx and Novo Nordisk hope to discover and develop novel multi-specific drug candidates using Ablynx's proprietary Nanobody technology...
15 October 2015 | By Victoria White
The nanobody construct binds to two different immune modulators, proteins believed to be targets for the development of important cancer immunotherapies...
22 July 2015 | By Victoria White
Ablynx has expanded its immuno-oncology collaboration with MSD to address an increased number of immune checkpoint modulator targets...
18 May 2015 | By Victoria White
Ablynx is set to collaborate with Genzyme to investigate Nanobodies against a target that plays an important role in multiple sclerosis (MS)...